GENETIC TECHNOLOGIES LIMITED — Board/Management Information 2018

Jan 29, 2018

==> picture [590 x 69] intentionally omitted <==

==> picture [590 x 70] intentionally omitted <==

ASX ANNOUNCEMENT 30 January 2018

Resignation of Directors

Melbourne, Australia, 30 January, 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), advises that Dr Malcolm R. Brandon and Mr Grahame Leonard, AM have resigned as directors of the Company with immediate effect.

The Shareholders General Meeting scheduled to take place at 10.00 am, AEST on 31 January, 2018 will still take place to enable shareholders to have the opportunity to vote on the resolutions raised in the notice of meeting.

The Company would like to thank Dr Brandon and Mr Leonard for their contributions during their respective periods of appointment.

FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Eutillio Buccilli

Executive Director & Chief Executive Officer Blueprint Life Science Group Genetic Technologies Limited + 1 (415) 375 3340, Ext. 4 + 61 3 8412 7050

About Genetic Technologies Limited

Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGen plus[®] , is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGen plus is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.

The Company markets BREVAGen plus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

==> picture [590 x 69] intentionally omitted <==

==> picture [590 x 70] intentionally omitted <==

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040